

#### **Philosophy and Process**

Harding Loevner believes a diversified portfolio of high-quality, durable-growth companies purchased at reasonable prices will provide superior investment returns with below-average risk over the long term. Our analysts conduct careful bottom-up research of individual companies and analyze the competitive dynamics of their industries to identify the best growth companies and to assess the value of their shares. To qualify for investment, companies must be well managed, financially strong, and possess clear competitive advantages relative to their peers.

#### **Investment Objective**

The investment objective of the active Fund is to achieve long-term capital appreciation by investing primarily in global equities.

## **Fund Facts**

| Domicile/Type       | Ireland/UCITS                |
|---------------------|------------------------------|
| Base Currency       | US Dollar                    |
| Benchmark           | MSCI All Country World Index |
| Fund Inception      | 17 June 2022                 |
| Total Fund Assets   | US \$99.7M                   |
| Sales Charges       | None                         |
| Number of Holdings  | 67                           |
| Total Expense Ratio | 0.80%                        |
| Listing/Dealing     | None/Daily                   |
| Investment Manager  | - Harding Loevner LP         |
| Regulator           | Central Bank of Ireland      |
|                     |                              |

## **Portfolio Managers**

Peter Baughan, CFA Co-Lead Portfolio Manager Harding Loevner since 1997

Jingyi Li Co-Lead Portfolio Manager Harding Loevner since 2010

Scott Crawshaw Portfolio Manager Harding Loevner since 2014

**Christopher Mack, CFA** Portfolio Manager Harding Loevner since 2004

Richard Schmidt, CFA Portfolio Manager Harding Loevner since 2011

Moon Surana, CFA Portfolio Manager Harding Loevner since 2009

## Class X1 – US Dollar Performance (% Total Return) as of 30 September 2022

Performance data quoted represents past performance; past performance does not guarantee future results.

|   | 3 Months | Since Inception |
|---|----------|-----------------|
| Global Paris-Aligned Equity Fund <sup>1</sup> | -5.76    | -3.40           |
| MSCI All Country World Index <sup>2</sup>     | -6.82    | -4.79           |

Class X1 Inception date: 17 June 2022; Returns are annualized for periods greater than one year.

## Portfolio Positioning (% Weight)

| Sector             | Fund | Benchmark <sup>3</sup> |
|--------------------|------|------------------------|
| Comm Services      | 8.7  | 7.3                    |
| Cons Discretionary | 8.1  | 11.5                   |
| Cons Staples       | 2.6  | 7.7                    |
| Energy             | 0.0  | 5.2                    |
| Financials         | 14.6 | 14.5                   |
| Health Care        | 23.2 | 13.0                   |
| Industrials        | 16.9 | 9.5                    |
| Info Technology    | 22.5 | 20.8                   |
| Materials          | 0.0  | 4.7                    |
| Real Estate        | 0.5  | 2.7                    |
| Utilities          | 0.0  | 3.1                    |
| Cash               | 2.9  | _                      |

| 0.0<br>10.2<br>9.4 | 3.1<br>11.1<br>7.3               |
|--------------------|----------------------------------|
|                    |                                  |
| 9.4                | 7.3                              |
|                    |                                  |
| 10.0               | 7.9                              |
| 0.0                | -                                |
| 2.2                | 5.4                              |
| 0.0                | 0.2                              |
| 1.1                | 3.0                              |
| 64.2               | 62.0                             |
| 2.9                | -                                |
|                    | 0.0<br>2.2<br>0.0<br>1.1<br>64.2 |

## **Portfolio Characteristics**

| Quality and Growth                       | Fund | Benchmark <sup>3</sup> |
|--|------|------------------------|
| Profit Margin <sup>5</sup> (%)           | 19.5 | 16.1                   |
| Return on Assets <sup>5</sup> (%)        | 9.6  | 8.9                    |
| Return on Equity <sup>5</sup> (%)        | 20.5 | 20.5                   |
| Debt/Equity Ratio <sup>5</sup> (%)       | 42.4 | 70.6                   |
| Std. Dev. of 5 Year ROE <sup>5</sup> (%) | 4.8  | 6.7                    |
| Sales Growth <sup>5,6</sup> (%)          | 14.7 | 8.5                    |
| Earnings Growth <sup>5,6</sup> (%)       | 22.0 | 16.2                   |
| Cash Flow Growth <sup>5,6</sup> (%)      | 18.1 | 13.0                   |
| Dividend Growth <sup>5,6</sup> (%)       | 11.1 | 8.2                    |

| Size and Valuation           | Fund  | Benchmark <sup>3</sup> |
|------------------------------|-------|------------------------|
| Wtd. Med. Mkt. Cap. (US\$B)  | 69.2  | 72.8                   |
| Wtd. Avg. Mkt. Cap. (US\$B)  | 242.9 | 305.8                  |
| Price/Earnings <sup>7</sup>  | 24.8  | 14.6                   |
| Price/Cash Flow <sup>7</sup> | 18.8  | 10.1                   |
| Price/Book <sup>7</sup>      | 4.3   | 2.3                    |
| Dividend Yield <sup>8</sup>  | 0.9   | 2.4                    |

## Performance (% Total Return) as of 30 September 2022

|                 | Class X1          |                    |
|-----------------|-------------------|--------------------|
|                 | US Dollar         |                    |
|                 | Fund <sup>1</sup> | Index <sup>2</sup> |
| 3 Months        | -5.76             | -6.82              |
| 1 Year          | -                 | _                  |
| 3 Years         | -                 | _                  |
| Since Inception | -3.40             | -4.79              |

Class X1 inception date: 17 June 2022; Returns are annualized for periods greater than one year.

## **Class Offerings**

| Class I   | Inception | Min. Investment | SEDOL/CUSIP | ISIN         | NAV | Distribution Policy | Total Exp.<br>Ratio <sup>9</sup> | Fee Cap <sup>10</sup> |
|-----------|-----------|-----------------|-------------|--------------|-----|---------------------|----------------------------------|-----------------------|
| US Dollar | -         | US\$1M          | BNMBS41     | IE0002RVG3I2 | -   | No Entitlement      | 0.80%                            | 0.80%                 |

Additional currency classes may be available for investment beyond those listed. No share classes engage in currency hedging. Currency class designations do not represent disparate currency exposure.

### **Ten Largest Holdings**

| Vertex PharmaceuticalsHealth CareUSJohn DeereIndustrialsUSAlphabetComm ServicesUSFirst Republic BankFinancialsUSSVB Financial GroupFinancialsUSSchneider ElectricIndustrialsFranceMicrosoftInfo TechnologyUSUnitedHealth GroupHealth CareUSAmetekIndustrialsUSAmazon.comCons DiscretionaryUS | · · · · _ · · g · · · · · · · · · · g · | Sector             | Market | % Assets |
|--|---|--------------------|--------|----------|
| AlphabetComm ServicesUSFirst Republic BankFinancialsUSSVB Financial GroupFinancialsUSSchneider ElectricIndustrialsFranceMicrosoftInfo TechnologyUSUnitedHealth GroupHealth CareUSAmetekIndustrialsUSAmazon.comCons DiscretionaryUS   | Vertex Pharmaceuticals                  | Health Care        | US     | 3.9      |
| First Republic BankFinancialsUSSVB Financial GroupFinancialsUSSchneider ElectricIndustrialsFranceMicrosoftInfo TechnologyUSUnited Health GroupHealth CareUSAmetekIndustrialsUSAmazon.comCons DiscretionaryUS   | John Deere                              | Industrials        | US     | 3.7      |
| SVB Financial GroupFinancialsUSSchneider ElectricIndustrialsFranceMicrosoftInfo TechnologyUSUnitedHealth GroupHealth CareUSAmetekIndustrialsUSAmazon.comCons DiscretionaryUS   | Alphabet                                | Comm Services      | US     | 3.5      |
| Schneider ElectricIndustrialsFranceMicrosoftInfo TechnologyUSUnitedHealth GroupHealth CareUSAmetekIndustrialsUSAmazon.comCons DiscretionaryUS  | First Republic Bank                     | Financials         | US     | 3.1      |
| MicrosoftInfo TechnologyUSUnitedHealth GroupHealth CareUSAmetekIndustrialsUSAmazon.comCons DiscretionaryUS   | SVB Financial Group                     | Financials         | US     | 2.9      |
| UnitedHealth GroupHealth CareUSAmetekIndustrialsUSAmazon.comCons DiscretionaryUS   | Schneider Electric                      | Industrials        | France | 2.9      |
| AmetekIndustrialsUSAmazon.comCons DiscretionaryUS  | Microsoft                               | Info Technology    | US     | 2.7      |
| Amazon.com Cons Discretionary US   | UnitedHealth Group                      | Health Care        | US     | 2.6      |
|  | Ametek                                  | Industrials        | US     | 2.5      |
| Ten Largest Holdings   | Amazon.com                              | Cons Discretionary | US     | 2.5      |
|  | Ten Largest Holdings                    |                    |        | 30.3     |

#### Contact

Harding Loevner – Transfer Agency c/o Northern Trust International Fund Administration Services (Ireland) Ltd. George's Court, 54-62 Townsend Street Dublin 2, Ireland HardingLoevnerTAdublin@ntrs.com Tel: +353 1 434 5085 Fax: +353 1 434 5289 hardingloevnerfundsplc.com

#### **Risk Factors**

Securities in the Fund are subject to market fluctuations and other risks inherent in investing in securities. Fund shares are priced daily and will fluctuate. The value of your principal investment will fluctuate accordingly and may be worth more or less than your original investment. Changes in exchange rates between currencies or the conversion from one currency to another may also cause the value of the investments to diminish or increase. An investment in a Fund should not constitute a substantial proportion of an investment portfolio and may not be appropriate for all investors. For further discussion of risk factors, refer to the Risk Factors section of the Company's prospectus and the applicable Fund's Supplement to the prospectus.

# Endnotes

### Pages 1 and 2

(1) Net of fees (2) Net of withholding taxes (3) MSCI All Country World Index (4) Includes countries with less-developed markets outside the Index (5) Weighted median (6) Trailing five years, annualized (7) Weighted harmonic mean (8) Weighted mean (9) Total expense ratio (TER) based on the investment management fees listed in the most recent prospectus supplement and the operating expenses incurred in the fiscal year (10) Harding Loevner has agreed to cap the TER as provided in the table on the previous page.

#### Disclosures

Source (Sector and Geographic Positioning, Largest Holdings and other Characteristics): FactSet; Harding Loevner Funds plc Global Paris-Aligned Equity Fund; MSCI Inc, and S&P. Characteristics run date: 05 October 2022, based on the latest available data in FactSet on this date.

MSCI Inc. and S&P do not make any express or implied warranties or representations and shall have no liability whatsoever with respect to any GICS data contained herein.

The information contained herein concerns a sub-fund (the "Fund") of Harding Loevner Funds plc (the "Company"), an umbrella-type open-ended investment company with segregated liability between sub-funds authorized in Ireland as an undertaking for collective investment in transferable securities (a "UCITS") pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011, as amended. Harding Loevner LP is the investment manager of the Company. The latest version of the prospectus and applicable KIIDs, as well as a summary of investor rights, may be obtained at hardingloevnerfundsplc.com.

There can be no assurance that the Fund's investment objective will be achieved, and investment results may vary substantially over time. This document is a marketing communication, is for information purposes only, and does not constitute an offer or invitation to purchase shares in the Fund and has not been prepared in connection with any such offer or invitation. The Fund has the ability to terminate arrangements for marketing in accordance with Article 93a of Directive 2009/65/EC. Please consult the Company's prospectus, applicable Fund's Supplement, and applicable KIID before making any final investment decision.

